1186 related articles for article (PubMed ID: 27740967)
21. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
22. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
24. Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.
Kadota K; Yeh YC; D'Angelo SP; Moreira AL; Kuk D; Sima CS; Riely GJ; Arcila ME; Kris MG; Rusch VW; Adusumilli PS; Travis WD
Am J Surg Pathol; 2014 Aug; 38(8):1118-27. PubMed ID: 25029118
[TBL] [Abstract][Full Text] [Related]
25. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
[TBL] [Abstract][Full Text] [Related]
26. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
27. Impact of GLUT1 and Ki-67 expression on early‑stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification.
Maki Y; Soh J; Ichimura K; Shien K; Furukawa M; Muraoka T; Tanaka N; Ueno T; Yamamoto H; Asano H; Tsukuda K; Toyooka S; Miyoshi S
Oncol Rep; 2013 Jan; 29(1):133-40. PubMed ID: 23076555
[TBL] [Abstract][Full Text] [Related]
28. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.
Yip PY; Yu B; Cooper WA; Selinger CI; Ng CC; Kennedy CW; Kohonen-Corish MR; McCaughan BC; Trent RJ; Boyer MJ; Kench JG; Horvath LG; O'Toole SA
J Thorac Oncol; 2013 Apr; 8(4):408-14. PubMed ID: 23392229
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.
Seo AN; Yang JM; Kim H; Jheon S; Kim K; Lee CT; Jin Y; Yun S; Chung JH; Paik JH
Br J Cancer; 2014 May; 110(11):2688-99. PubMed ID: 24809777
[TBL] [Abstract][Full Text] [Related]
30. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
31. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive study of mutational and clinicopathologic characteristics of adenocarcinoma with lepidic pattern in surgical resected lung adenocarcinoma.
Xu Y; Zhu C; Qian W; Zheng M
J Cancer Res Clin Oncol; 2017 Jan; 143(1):181-186. PubMed ID: 27738759
[TBL] [Abstract][Full Text] [Related]
33. Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.
Li H; Pan Y; Li Y; Li C; Wang R; Hu H; Zhang Y; Ye T; Wang L; Shen L; Sun Y; Chen H
Lung Cancer; 2013 Jan; 79(1):8-13. PubMed ID: 23098378
[TBL] [Abstract][Full Text] [Related]
34. Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas.
Yu HA; Sima CS; Shen R; Kass S; Gainor J; Shaw A; Hames M; Iams W; Aston J; Lovly CM; Horn L; Lydon C; Oxnard GR; Kris MG; Ladanyi M; Riely GJ
J Thorac Oncol; 2015 Mar; 10(3):431-7. PubMed ID: 25415430
[TBL] [Abstract][Full Text] [Related]
35. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
36. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Yoshida T; Ishii G; Goto K; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Nagai K; Ohe Y; Ochiai A
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1691-700. PubMed ID: 23974272
[TBL] [Abstract][Full Text] [Related]
37. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
38. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
39. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
